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Abstract Breast cancer at a relatively young age with a
poor prognosis is currently exhibiting an increasing
incidence. In a retrospective cohort analysis of early breast
cancer cases after surgery from our institutional patient
registry, 141 patients aged ≤40 years constituted the
younger group, with 300 randomly selected patients
aged >40 years as controls. A significant and steady
increase was found in the relative number of younger cases
during the years 2004–2009. The histological type and
grade and the lymph node status of the cancers differed
significantly between the two groups, with more aggressive
biological behaviour, a more advanced stage and a worse
prognosis in the younger group. Half of the cancers in the
younger cohort were ER-negative, while two-thirds in the
control group were ER-positive. Comparatively more tumours
were PR-positive and HER2-negative in the control group
than in the younger group. The rates of triple-negative cases
were 25% and 13% in the younger age and the control group,
respectively (p=0.026). Significantly higher mastectomy and
axillary block dissection rates were observed in the younger
age group, and more chemotherapy was administered than in
the control group. Our findings demonstrate the significance
of breast cancer in cases aged <40 years, and draw attention
to the need for appropriate care in these cases.
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Abbreviations
ER oestrogen receptor
HER2 human epidermal growth factor receptor type 2
pN pathological lymph node status
pT pathological tumour size
PR progesterone receptor
DCIS ductal carcinoma in situ
IDC invasive ductal carcinoma
ILC invasive lobular carcinoma
Introduction
An increasing incidence of breast cancer at a comparatively
young age has recently been demonstrated in many
countries worldwide [1–3]. Among women aged <40 years,
breast cancer is the most frequent form of cancer,
accounting for 30–40% of all malignancies [4], with
reported breast cancer incidences of 4–7% in different
populations [5–7].
Breast cancer at a young age has been shown to be
associated with a poor prognosis, in part because of the
generally more aggressive nature and the more advanced
stage in younger than in older women [8–10]. Most studies
have revealed an increased proportion of high-grade,
rapidly proliferating tumours accompanied by vascular
invasion and regional lymph node involvement in younger
patients [8–10]. Genomic analysis suggests a distinct
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biological entity with less frequent hormonesensitivity and
a greater HER1-2 dependence [11]. An age <35 years has
itself been demonstrated to be an independent unfavourable
prognostic factor [4].
The National Cancer Registry indicates that, the incidence
of breast cancers in women aged <40 years in Hungary is
about 5% (Fig. 1). Our impression that we were seeing
increasing numbers of young breast cancer patients in our
everyday practice led us to perform an analysis on the
proportions of such patients at our department, in conjunc-
tion with the tumour- and treatment-related features extracted
from the available patient registry data. As a cut-off point for
the analysis, we chose the age limit of 40 years similarly to
most other investigators in the literature [2, 4, 6, 8, 12].
Materials and Methods
A retrospective cohort analysis was performed on the early
breast cancer cases after surgery, retrieved from the institu-
tional patient registry. Patients aged ≤40 years (141 women
had attended our department between January 1998 and
August 2009) constituted the younger group, with 300
randomly selected patients aged >40 years (treated between
January 2004 and August 2009) as controls. The annual
distribution of the younger cases and various clinical data
were collected: the age of the patient at the time of surgery, the
types of breast and lymph node surgery, the histological type
and grade of the tumour, the pathological tumour size (pT) and
lymph node status (pN), the hormone receptor (oestrogen
receptor (ER), progesterone receptor (PR) and the human
epidermal growth factor receptor type 2 (HER2) status of the
tumour, and the nature of the systemic therapy. Tumour
characteristics were determined by standardized methods that
did not significantly change over the study period.
Statistical analyses were performed with Fisher’s exact
probability test and linear regression analysis. A p value
of<0.05 was regarded as statistically significant.
Results
The mean (± standard deviation) ages of the 141 younger
and the 300 control cases were 35.1±3.7 (23–40) and
58.9±9.9 (41–84) years, respectively. After a level state in
years 1998–2003, we found a steadily increasing relative
number of new breast cancer in to the younger group
between 2004 and 2009 (p=0.035). The proportion of
younger cases reached 13% by 2009, clearly different from
the respective data registered in the national database
throughout the same time period (Figs. 1 and 2).
The rates of mastectomy in the younger and control groups
were 41.7% and 31.4%, respectively (p=0.046), those of
axillary block dissection were 80% and 67%, respectively
(p=0.007), and those of sentinel lymph node biopsy only
were 19.8% and 33.1%, respectively (p=0.007).
The most common histological type in both age groups
was invasive ductal carcinoma (IDC) (Table 1). Signifi-
cantly more medullary cancers occurred in the younger
group than in the control group, while in the control group,
in contrast with the younger patients, the second most
frequent histological type was invasive lobular carcinoma
(ILC). Poorly-differentiated high-grade tumours occurred
significantly more frequently in the younger group, whilst
well-differentiated and moderately-differentiated cancers
were significantly more frequent among the controls
(Table 1). No difference was observed in the pT status of
the tumours. Significantly more pN0 tumours were noted in
the control group, while the number of pN2 cases was
significantly higher among the younger patients. Half of the
cancers in the younger cohort were ER-negative, while two-
thirds of those in the control group were ER-positive (p<
0.001). Comparatively more tumours were PR-positive and
HER2-negative in the control group than in the younger
group. The proportion of ER- and PR-positive tumours
was, however, significantly higher in the young age than in
the control group (p=0.006). The rates of triple-negative
Fig. 1 Annual number of new breast cancer patients aged ≤40 years
in proportion to the total number of all breast cancer cases in Hungary
in 2004–2008 according to the National Cancer Registry (courtesy of
Dr. István Gaudi)
Fig. 2 Annual number of new breast cancer patients aged ≤40 years
in proportion to the total number of all breast cancer cases at the
Department of Oncotherapy, University of Szeged, in the period
2004–2009
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cases in the younger and control groups were 25% and
13%, respectively (p=0.026) (Table 1). No significant
differences were detected in the number of ER- and
HER2-positive or grade 3 and ER-positive cases between
the studied groups. Significantly more of the younger
patients received chemotherapy (86.4% vs. 47.4%, p<
0.001), and a taxane-based chemotherapy (48.2% vs. 12.5%
of all chemotherapies, p<0.001), whereas significantly
more control patients received hormone therapy (64.1%
vs. 50.4%, p=0.014). While 16 patients in the young age
group received neoadjuvant chemotherapy, no such therapy
was given in the control group.
Discussion
Our analysis confirmed a steady relative increase in the
attendance at our department of breast cancer patients
aged ≤40 years. Prognostic factors relating to biological
behaviour, such as the histological type, grade, ER/PR
status or stage, including the lymph node status, indicate
more aggressive biological behaviour and a more ad-
vanced stage, with a worse overall prognosis, among these
patients as compared with those >40 years.
An increase in the incidence of breast cancer at a
comparatively young age has recently been demonstrated in
Table 1 Pathological features of breast cancers in the younger and the control groups
Tumour features Patients ≤40 years (n=141) Patients >40 years (n=300) p
% n % n
Histolo-gical type DCIS 4.3 6 8.7 26 0.116
IDC 75.9 107 71.3 214 0.359
medullary 4.3 6 1.0 3 0.033
ILC 3.5 5 13.0 39 0.002
other 12.0 17 6.0 18 0.037
pT 1–9 mm 9.9 14 14.3 43 0.225
10–14 mm 21.3 30 23.0 69 0.715
15–20 mm 22.7 32 24.7 74 0.720
>20 mm 40.4 57 38.0 114 0.675
unknown 5.7 8 0 0 –
pN pN0 58.9 83 74.3 223 0.001
pN1 16.3 23 17.3 52 0.892
pN2 14.9 21 5.00 15 0.001
pN3 6.4 9 3.4 10 0.206
unknown 3.5 5 0 0 –
Grade Grade 1 5.7 8 15.7 47 0.003
Grade 2 29.8 42 43.3 130 0.007
Grade 3 53.9 76 40.3 121 0.010
Grade unknown 10.6 15 0.7 2 <0.001
ER ER-positive 48.2 68 71.7 215 <0.001
ER-negative 45.4 64 28.0 84 0.001
ER unknown 6.4 9 0.3 1 <0.001
proportion of ER-positive cells in
ER-positive tumours (mean±SD)
61.0±22.55 74.0±17.69 0.070
PR PR-positive 56.7 80 67.3 202 0.034
PR-negative 38.3 54 32.0 96 0.198
PR unknown 4.96 7 0.7 2 0.006
proportion of PR-positive cells in
PR-positive tumours (mean±SD)
67.0±19.52 70.3±19.51 0.761
HER2 HER2-negative 69.5 98 81.7 245 0.007
HER2 2/3+ 22.7 32 18.0 54 0.249
HER2 unknown 7.8 11 0.3 1 <0.001
ER, PR and HER2-negative 25.2 31/123 13.5 40/297 0.026
ER-positive and PR-negative 6.6 9/136 16.1 48/298 0.006
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both well-developed and developing countries [1–3].
During the period 2004–2009, we found a roughly 50%
yearly increase in the relative number of breast cancer
patients aged ≤40 years attending our institute. On the basis
of the data of the Geneva Cancer Registry, Bouchardy et al.
reported an increase of the same magnitude in breast cancer
cases among those aged ≤40 years in 2002–2004, after a
steady state in the previous years. A major limitation of our
analysis is that it is based on service data rather than
population-based data, and thus no firm conclusions may be
drawn on the changes in the incidence of the disease in this
subgroup of women.
It has been suggested that, while the prognostic factors
are poor in young breast cancer patients [4], the mortality
rates are improving, probably as a result of the earlier
diagnosis due to better breast-awareness and modern, more
efficient therapy [13]. Although we did not analyse the
outcome, the overall prognosis and the biological features
of the breast cancers clearly differed between the cases in
the younger and the control groups. The tumour character-
istics were consistent with the findings of other studies [4,
6, 8, 10, 14], though mention should be made of the
retrospective analysis by McAree et al., in which many of
the pathological features were similar to those we
observed, but medullary cancers were absent, and the
high rate (76.8%) of ER-positive and the low rate (10.5%)
of triple-negative breast cancers were striking among
those aged <40 years [6]. In one group of breast cancer
patients diagnosed under the age of 35, the proportion of
“basal-like” breast cancers was 23% [12]. Since the rates of
medullary and triple-negative cases were outstanding
among the younger cases in our database, it may be
speculated that BRCA1 mutation carriers were possibly
over-represented, but no information on the genetic
background of the patients was available. The differences
between the two groups as regards surgical and medical
therapy reflected the differences in stage and the biological
features of the tumours.
Our findings demonstrate that breast cancer is not rare
before the age of 40 years, and can then demonstrate
particularly aggressive behaviour and a poor prognosis.
Vigilance is needed to ensure its recognition and the
provision of appropriate therapy.
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